Lisata Therapeutics Inc (LSTA) Stock Price, Quote & News

Latest News on LSTA

Jan 15, 2025, 8:30 AM EST - 2 days ago

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

Dec 10, 2024, 8:30 AM EST - 5 weeks ago

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

Nov 19, 2024, 8:30 AM EST - 2 months ago

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year'

Nov 12, 2024, 10:07 PM EST - 2 months ago

Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 2 months ago

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 9:23 AM EST - 2 months ago

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

Nov 6, 2024, 8:30 AM EST - 2 months ago

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

Oct 31, 2024, 8:30 AM EDT - 2 months ago

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

Oct 28, 2024, 8:30 AM EDT - 2 months ago

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

Sep 9, 2024, 8:00 AM EDT - 4 months ago

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

Sep 5, 2024, 8:00 AM EDT - 4 months ago

Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

Aug 13, 2024, 12:20 AM EDT - 5 months ago

Lisata Therapeutics, Inc. (LSTA) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 8:00 AM EDT - 6 months ago

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

Jul 16, 2024, 8:00 AM EDT - 6 months ago

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Jul 10, 2024, 8:00 AM EDT - 6 months ago

Lisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

Jun 13, 2024, 8:30 AM EDT - 7 months ago

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

May 28, 2024, 8:30 AM EDT - 8 months ago

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

May 20, 2024, 8:30 AM EDT - 8 months ago

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

May 9, 2024, 9:42 PM EDT - 9 months ago

Lisata Therapeutics, Inc. (LSTA) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 9 months ago

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 8:00 AM EDT - 9 months ago

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

Apr 23, 2024, 7:30 AM EDT - 9 months ago

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Apr 9, 2024, 8:30 AM EDT - 10 months ago

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Apr 3, 2024, 8:30 AM EDT - 10 months ago

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

Mar 21, 2024, 8:00 AM EDT - 10 months ago

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Feb 29, 2024, 8:41 PM EST - 11 months ago

Lisata Therapeutics, Inc. (LSTA) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:05 PM EST - 11 months ago

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Feb 22, 2024, 8:00 AM EST - 11 months ago

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

Feb 20, 2024, 8:00 AM EST - 11 months ago

Lisata Therapeutics to Present at BIO CEO & Investor Conference

Jan 18, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico

Jan 4, 2024, 8:00 AM EST - 1 year ago

Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

Nov 28, 2023, 4:05 PM EST - 1 year ago

Lisata Therapeutics to Present at NobleCon19 Investor Conference

Nov 4, 2023, 10:27 AM EDT - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q3 2023 Earnings Call Transcript

Oct 26, 2023, 8:00 AM EDT - 1 year ago

Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time

Oct 24, 2023, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide

Oct 17, 2023, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer

Sep 28, 2023, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces Participation in Upcoming Conferences in October

Sep 12, 2023, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors

Aug 17, 2023, 5:30 PM EDT - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q2 2023 Earnings Call Transcript

Aug 15, 2023, 8:30 AM EDT - 1 year ago

Impilo Therapeutics Launches to Enable Nucleic Acid-Based Medicines to Effectively Treat Solid Tumor Cancers

Aug 14, 2023, 4:05 PM EDT - 1 year ago

Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 8, 2023, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma

Aug 7, 2023, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time

Jul 11, 2023, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors

Jun 12, 2023, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference

May 12, 2023, 3:30 PM EDT - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q1 2023 Earnings Call Transcript

May 9, 2023, 4:05 PM EDT - 1 year ago

Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023, 9:07 AM EDT - 1 year ago

Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time

Apr 20, 2023, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

Apr 18, 2023, 8:30 AM EDT - 1 year ago

Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

Market Cap	31.23M
Revenue (ttm)	0.00
Net Income (ttm)	-20.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	71,800
Avg Vol	32,200
Day's Range	N/A - N/A
Shares Out	8.40M
Stochastic %K	60%
Beta	1.14
Analysts	Strong Sell
Price Target	$14.00